文献速递肿瘤 PET/CT

18F-FDG PET与CT扫描可检测接受抗程序性死亡1免疫检查点抑制剂治疗的霍奇金淋巴瘤患者的新影像学缓解与进展模式

18F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-Programmed Death 1 Immune Checkpoint Inhibitor.
PubMed 文献 · J Nucl Med · 2017-06-08

回顾性纳入2013—2015年Gustave Roussy接受抗PD1(帕博利珠单抗或纳武利尤单抗)治疗的16例复发或难治性经典霍奇金淋巴瘤患者,每3个月行18F-FDG PET/CT与增强CT。3个月时18F-FDG PET/CT识别出全部缓解者,并在5例中重新分类最佳总体缓解;5例(31%)出现与抗PD1相关的新影像模式。

要点

  • 16例中9例(56%)达客观缓解,3个月18F-FDG PET/CT可识别全部缓解者。
  • 与单独CT相比,3个月18F-FDG PET/CT在5例中重新分类最佳总体缓解。
  • 5/16例(31%)出现新影像模式:2例LYRIC 2016判定的暂时性进展、3例新病灶伴免疫相关不良事件。

核心结论

  • 3个月18F-FDG PET/CT可检测对anti-PD1应答的霍奇金淋巴瘤患者,31%患者出现新影像模式,强调需在更大系列中进一步评估并由影像与肿瘤专科医生逐例密切协作。

研究设计与样本

  • 回顾性连续纳入2013至2015年在Gustave Roussy接受抗PD1(帕博利珠单抗或纳武利尤单抗)治疗的复发或难治性经典霍奇金淋巴瘤患者16例。
  • 每3个月采集18F-FDG PET/CT与增强CT,按国际协调项目Cheson 2014标准与LYRIC(2016修订标准)记录最佳总体缓解。
  • 抗PD1治疗期间任何时间达客观缓解者归为缓解者。

主要发现

  • 16例患者中位年龄39岁(范围19—69岁),既往治疗中位线数6(范围3—13),平均随访22.6个月。
  • 16例中9例(56%)达客观缓解,2例于7个月时因疾病进展死亡。
  • 3个月时18F-FDG PET/CT识别出全部缓解者,与单独CT相比在5例中重新分类最佳总体缓解。
  • 缓解者3个月时肿瘤代谢与体积(SUVmean、代谢性肿瘤体积)下降、健康脾脏代谢升高(曲线下面积>0.85,P<0.04)。
  • 5/16例(31%)出现与抗PD1相关的新影像模式:2例暂时性进展符合LYRIC(2016)不确定缓解(14个月IR2b、18个月IR3),3例新病灶伴免疫相关不良事件。

关键数值与推荐

  • 缓解评估采用国际协调项目Cheson 2014标准与LYRIC 2016修订标准。
  • 缓解者3个月时肿瘤代谢与体积(SUVmean、代谢性肿瘤体积)下降及健康脾脏代谢升高,曲线下面积>0.85,P<0.04。
  • 5/16例(31%)出现新影像模式,其中2例符合LYRIC(2016)不确定缓解(14个月IR2b、18个月IR3),3例新病灶伴免疫相关不良事件。

临床怎么用

  • 原文结论强调需在更大系列中进一步评估新影像模式,并由影像与肿瘤专科医生逐例密切协作。

局限性

  • 原文结论指出需在更大系列中进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The response evaluation criteria in patients with Hodgkin lymphoma (HL) were designed for the assessment of chemotherapy and targeted molecular agents. We investigated the accuracy of 3-mo 18F-FDG PET/CT for the identification of HL patients responding to immune-checkpoint blockade by anti-programmed death 1 antibodies (anti-PD1). We also reported the frequency of new immune patterns of response and progression. Methods: Retrospectively, we recruited consecutive HL patients treated by anti-PD1 (pembrolizumab or nivolumab) at Gustave Roussy from 2013 to 2015. 18F-FDG PET/CT and contrast-enhanced CT scans were acquired every 3 mo. We recorded the best overall response according to the International Harmonization Project Cheson 2014 criteria and LYmphoma Response to Immunomodulatory therapy Criteria (LYRIC) (2016 revised criteria). Patients achieving an objective response at any time during the anti-PD1 treatment were classified as responders. Results: Sixteen relapsed or refractory classic HL patients were included. The median age was 39 y (age range, 19-69 y). The median previous lines of therapy was 6 (range, 3-13). The mean follow-up was 22.6 mo. Nine of 16 patients (56%) achieved an objective response. Two deaths occurred due to progressive disease at 7 mo. 18F-FDG PET/CT detected all responders at 3 mo and reclassified best overall response in 5 patients compared with CT alone. A decrease in tumor metabolism and volume (SUVmean, metabolic tumor volume) and increase in healthy splenic metabolism at 3 mo were observed in responders (area under the curve > 0.85, P < 0.04). Five of 16 patients (31%) displayed new imaging patterns related to anti-PD1; we observed 2 transient progressions consistent with indeterminate response according to the LYRIC (2016) (IR2b at 14 mo and IR3 at 18 mo) and 3 patients with new lesions associated with immune-related adverse events. Conclusion: Three-month 18F-FDG PET/CT scans detected HL patients responding to anti-PD1. New patterns were encountered in 31% of patients, emphasizing the need for further evaluation in larger series and close collaboration between imaging and oncology specialists on a per-patient basis.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Dercle L, Seban RD, Lazarovici J, et al. 18F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-Programmed Death 1 Immune Checkpoint Inhibitor. J Nucl Med. 2017. PMID: 28596157. doi:10.2967/jnumed.117.193011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。